PRNewswire reports, Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, announced that it is partnering with the International Vaccine Institute (IVI) to support the recently launched Dengue Vaccine Initiative (DVI). Sanofi Pasteur and the IVI will aim to raise awareness and to work to move dengue vaccination higher on the global health agenda. Currently, there is no specific treatment available for dengue fever, which is a threat to nearly half of the world''s population and a public health priority in many countries of Latin America and Asia where epidemics occur. Of the estimated 220 million people infected annually, two million-mostly children-develop dengue hemorrhagic fever, a severe form of the disease. DHF is a leading cause of hospitalization, placing tremendous pressure on strained medical resources and having a heavy economic and societal impact. Sanofi Pasteur''s candidate dengue vaccine-which targets all four virus serotypes- is in Phase 3 clinical study. Phase 3 studies are the ultimate steps in the clinical development of a vaccine before it is submitted to regulatory authorities for evaluation for market authorization. Sanofi Pasteur candidate dengue vaccine has been evaluated in clinical studies (Phase 1, 2) in adults and children in the U.S., Asia and Latin America.